United Therapeutics Corp.
Cash Flow History
| Period | Operating Cash Flow | Free Cash Flow | CapEx | Share-Based Compensation |
|---|---|---|---|---|
| Mar 2017 | $230.8M | $215.2M | $15.6M | $-19.1M |
| Jun 2017 | $70.7M | $49.8M | $20.9M | — |
| Sep 2017 | $258.5M | $236.5M | $22.0M | — |
| Mar 2018 | $275.7M | $238.1M | $37.6M | $-101.1M |
| Jun 2018 | $179.8M | $126.3M | $53.5M | — |
| Sep 2018 | $237.5M | $196.0M | $41.5M | — |
| Mar 2019 | $-627.4M | $-652.5M | $25.1M | $29.2M |
| Jun 2019 | $132.9M | $112.6M | $20.3M | — |
| Sep 2019 | $185.4M | $171.8M | $13.6M | — |
| Mar 2020 | $214.6M | $201.6M | $13.0M | $30.8M |
| Jun 2020 | $164.0M | $145.8M | $18.2M | — |
| Sep 2020 | $250.9M | $235.1M | $15.8M | — |
| Mar 2021 | $89.8M | $79.2M | $10.6M | $40.1M |
| Jun 2021 | $148.2M | $131.9M | $16.3M | — |
| Sep 2021 | $185.6M | $162.3M | $23.3M | — |
| Mar 2022 | $288.7M | $275.2M | $13.5M | $-21.1M |
| Jun 2022 | $127.0M | $110.0M | $17.0M | — |
| Sep 2022 | $258.6M | $189.8M | $68.8M | — |
| Mar 2023 | $374.8M | $333.5M | $41.3M | $-12.4M |
| Jun 2023 | $106.3M | $61.6M | $44.7M | — |
| Sep 2023 | $346.2M | $280.5M | $65.7M | — |
| Mar 2024 | $376.5M | $338.3M | $38.2M | $25.6M |
| Jun 2024 | $232.2M | $187.1M | $45.1M | — |
| Sep 2024 | $377.2M | $300.7M | $76.5M | — |
| Mar 2025 | $461.2M | $386.3M | $74.9M | $31.8M |
| Jun 2025 | $191.7M | $129.5M | $62.2M | — |
| Sep 2025 | $562.1M | $351.6M | $210.5M | — |
| Mar 2026 | $463.3M | $362.5M | $100.8M | $33.9M |
| Jun 2026 | $313.6M | $205.6M | $108.0M | — |